- Home
- GOSS vs OXSQ Comparison
GOSS vs OXSQ Comparison
Compare GOSS & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- OXSQ
- Stock Information
- Founded
- GOSS 2015
- OXSQ 2003
- Country
- GOSS United States
- OXSQ United States
- Employees
- GOSS N/A
- OXSQ N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- OXSQ Blank Checks
- Sector
- GOSS Health Care
- OXSQ Finance
- Exchange
- GOSS Nasdaq
- OXSQ Nasdaq
- Market Cap
- GOSS 212.8M
- OXSQ 190.1M
- IPO Year
- GOSS 2019
- OXSQ N/A
- Fundamental
- Price
- GOSS $1.40
- OXSQ $2.84
- Analyst Decision
- GOSS Strong Buy
- OXSQ
- Analyst Count
- GOSS 5
- OXSQ 0
- Target Price
- GOSS $9.20
- OXSQ N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- OXSQ 388.7K
- Earning Date
- GOSS 03-04-2025
- OXSQ 02-28-2025
- Dividend Yield
- GOSS N/A
- OXSQ 14.79%
- EPS Growth
- GOSS N/A
- OXSQ N/A
- EPS
- GOSS N/A
- OXSQ N/A
- Revenue
- GOSS $105,322,000.00
- OXSQ $44,787,853.00
- Revenue This Year
- GOSS N/A
- OXSQ N/A
- Revenue Next Year
- GOSS N/A
- OXSQ N/A
- P/E Ratio
- GOSS N/A
- OXSQ N/A
- Revenue Growth
- GOSS N/A
- OXSQ N/A
- 52 Week Low
- GOSS $0.50
- OXSQ $2.40
- 52 Week High
- GOSS $1.60
- OXSQ $3.29
- Technical
- Relative Strength Index (RSI)
- GOSS 67.09
- OXSQ 67.65
- Support Level
- GOSS $1.37
- OXSQ $2.78
- Resistance Level
- GOSS $1.55
- OXSQ $2.87
- Average True Range (ATR)
- GOSS 0.13
- OXSQ 0.04
- MACD
- GOSS 0.03
- OXSQ 0.01
- Stochastic Oscillator
- GOSS 75.81
- OXSQ 85.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.